New emerging drugs in soft tissue sarcoma

Amalia Milano, Gaetano Apice, Ettore Ferrari, Flavio Fazioli, Vincenzo de Rosa, Antonella Salzano de Luna, Rosario Vincenzo Iaffaioli, Francesco Caponigro

Research output: Contribution to journalArticle

Abstract

Doxorubicin and ifosfamide are the two most active drugs in the treatment of patients with advanced, soft tissue sarcoma (STS) of most histologic subtypes, aside from gastrointestinal stromal tumor (GIST). However, after failure of these drugs, alone or in combination, patients with advanced STS have few therapeutic options and the search for new active drugs is well worth pursuing. ET-743, a DNA minor groove binder, which blocks cell cycle progression in G2/M phase through a p53-independent apoptotic process, represents the most promising among novel compounds in STS, since recently completed phase II trials have consistently shown high survival, in spite of the relatively low incidence of major objective responses. The potential for combination with other active compounds further increases the appeal of ET-743. Imatinib mesylate is being tested also in STS other than GIST, which can overexpress one or more of the tyrosine kinases inhibited by imatinib; however, negative data have recently been presented. Clinical studies with a number of other compounds are ongoing or planned. However, investigators involved in the management of patients with advanced STS are to be increasingly aware of the emergence of new molecular targets and genetic profiles in different histologic subtypes, according to which treatment strategies should be adapted.

Original languageEnglish
Pages (from-to)74-84
Number of pages11
JournalCritical Reviews in Oncology/Hematology
Volume59
Issue number1
DOIs
Publication statusPublished - Jul 2006

Fingerprint

trabectedin
Sarcoma
Gastrointestinal Stromal Tumors
Pharmaceutical Preparations
Ifosfamide
G2 Phase
Cell Division
Protein-Tyrosine Kinases
Doxorubicin
Molecular Biology
Cell Cycle
Therapeutics
Research Personnel
Survival
DNA
Incidence
Imatinib Mesylate

Keywords

  • ET-743
  • Imatinib
  • New drugs
  • Soft tissue sarcoma

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

New emerging drugs in soft tissue sarcoma. / Milano, Amalia; Apice, Gaetano; Ferrari, Ettore; Fazioli, Flavio; de Rosa, Vincenzo; de Luna, Antonella Salzano; Iaffaioli, Rosario Vincenzo; Caponigro, Francesco.

In: Critical Reviews in Oncology/Hematology, Vol. 59, No. 1, 07.2006, p. 74-84.

Research output: Contribution to journalArticle

Milano, Amalia ; Apice, Gaetano ; Ferrari, Ettore ; Fazioli, Flavio ; de Rosa, Vincenzo ; de Luna, Antonella Salzano ; Iaffaioli, Rosario Vincenzo ; Caponigro, Francesco. / New emerging drugs in soft tissue sarcoma. In: Critical Reviews in Oncology/Hematology. 2006 ; Vol. 59, No. 1. pp. 74-84.
@article{c4ccf08f2046429daab50f4fba82b3ac,
title = "New emerging drugs in soft tissue sarcoma",
abstract = "Doxorubicin and ifosfamide are the two most active drugs in the treatment of patients with advanced, soft tissue sarcoma (STS) of most histologic subtypes, aside from gastrointestinal stromal tumor (GIST). However, after failure of these drugs, alone or in combination, patients with advanced STS have few therapeutic options and the search for new active drugs is well worth pursuing. ET-743, a DNA minor groove binder, which blocks cell cycle progression in G2/M phase through a p53-independent apoptotic process, represents the most promising among novel compounds in STS, since recently completed phase II trials have consistently shown high survival, in spite of the relatively low incidence of major objective responses. The potential for combination with other active compounds further increases the appeal of ET-743. Imatinib mesylate is being tested also in STS other than GIST, which can overexpress one or more of the tyrosine kinases inhibited by imatinib; however, negative data have recently been presented. Clinical studies with a number of other compounds are ongoing or planned. However, investigators involved in the management of patients with advanced STS are to be increasingly aware of the emergence of new molecular targets and genetic profiles in different histologic subtypes, according to which treatment strategies should be adapted.",
keywords = "ET-743, Imatinib, New drugs, Soft tissue sarcoma",
author = "Amalia Milano and Gaetano Apice and Ettore Ferrari and Flavio Fazioli and {de Rosa}, Vincenzo and {de Luna}, {Antonella Salzano} and Iaffaioli, {Rosario Vincenzo} and Francesco Caponigro",
year = "2006",
month = "7",
doi = "10.1016/j.critrevonc.2005.12.002",
language = "English",
volume = "59",
pages = "74--84",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - New emerging drugs in soft tissue sarcoma

AU - Milano, Amalia

AU - Apice, Gaetano

AU - Ferrari, Ettore

AU - Fazioli, Flavio

AU - de Rosa, Vincenzo

AU - de Luna, Antonella Salzano

AU - Iaffaioli, Rosario Vincenzo

AU - Caponigro, Francesco

PY - 2006/7

Y1 - 2006/7

N2 - Doxorubicin and ifosfamide are the two most active drugs in the treatment of patients with advanced, soft tissue sarcoma (STS) of most histologic subtypes, aside from gastrointestinal stromal tumor (GIST). However, after failure of these drugs, alone or in combination, patients with advanced STS have few therapeutic options and the search for new active drugs is well worth pursuing. ET-743, a DNA minor groove binder, which blocks cell cycle progression in G2/M phase through a p53-independent apoptotic process, represents the most promising among novel compounds in STS, since recently completed phase II trials have consistently shown high survival, in spite of the relatively low incidence of major objective responses. The potential for combination with other active compounds further increases the appeal of ET-743. Imatinib mesylate is being tested also in STS other than GIST, which can overexpress one or more of the tyrosine kinases inhibited by imatinib; however, negative data have recently been presented. Clinical studies with a number of other compounds are ongoing or planned. However, investigators involved in the management of patients with advanced STS are to be increasingly aware of the emergence of new molecular targets and genetic profiles in different histologic subtypes, according to which treatment strategies should be adapted.

AB - Doxorubicin and ifosfamide are the two most active drugs in the treatment of patients with advanced, soft tissue sarcoma (STS) of most histologic subtypes, aside from gastrointestinal stromal tumor (GIST). However, after failure of these drugs, alone or in combination, patients with advanced STS have few therapeutic options and the search for new active drugs is well worth pursuing. ET-743, a DNA minor groove binder, which blocks cell cycle progression in G2/M phase through a p53-independent apoptotic process, represents the most promising among novel compounds in STS, since recently completed phase II trials have consistently shown high survival, in spite of the relatively low incidence of major objective responses. The potential for combination with other active compounds further increases the appeal of ET-743. Imatinib mesylate is being tested also in STS other than GIST, which can overexpress one or more of the tyrosine kinases inhibited by imatinib; however, negative data have recently been presented. Clinical studies with a number of other compounds are ongoing or planned. However, investigators involved in the management of patients with advanced STS are to be increasingly aware of the emergence of new molecular targets and genetic profiles in different histologic subtypes, according to which treatment strategies should be adapted.

KW - ET-743

KW - Imatinib

KW - New drugs

KW - Soft tissue sarcoma

UR - http://www.scopus.com/inward/record.url?scp=33745142953&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745142953&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2005.12.002

DO - 10.1016/j.critrevonc.2005.12.002

M3 - Article

C2 - 16533604

AN - SCOPUS:33745142953

VL - 59

SP - 74

EP - 84

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 1

ER -